Defence Therapeutics Inc.
DTC
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.04% | -26.23% | -15.36% | -29.24% | 54.85% |
| Total Depreciation and Amortization | -15.11% | 13.01% | -3.15% | -2.31% | -63.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.44% | -27.89% | 28.63% | 44.84% | 20.02% |
| Change in Net Operating Assets | -405.12% | 105.36% | -840.96% | -128.60% | -19.16% |
| Cash from Operations | 12.08% | 57.21% | -191.25% | -844.93% | 116.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -41.67% | -- | -100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -70.00% |
| Total Debt Repaid | -357.58% | 85.33% | 82.63% | -365.83% | -256.41% |
| Issuance of Common Stock | -- | -100.00% | 426.88% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,220.29% | 97.21% | -1,056.07% | -- | -- |
| Cash from Financing | 18,004.05% | -100.27% | 492.80% | 5,032.98% | -122.49% |
| Foreign Exchange rate Adjustments | 344.44% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 229.05% | -145.09% | 271,720.00% | -100.91% | 116.34% |